Joining forces to tackle cholera
The urgent need for better cholera vaccines The World Health Organization (WHO) estimates 1.3–4 million cholera cases and 21,000–143,000 deaths each year, showing that cholera remains a significant global health ...
Extracellular vesicles moving toward the clinic
Ola’s insights and future perspectives from ISEV 2025 Looking back to April this year, the world’s most renowned experts in the field of extracellular vesicles gathered in Vienna for the ...
Moving into GMP – Turning process into product
The complex journey of bringing a biologic to market – part 4 The transition into GMP manufacturing marks a defining moment in the development of a biologic drug. After extensive ...
Optimization of the isolation method for large-scale production of synthetic bacterial vesicles for cancer immunotherapy
Abstract Negar Ordouzadeh, Rossella Crescitelli, Agnes Zimmer, Petra Tjärnlund, Cecilia Lässer, Jan Lötvall, Kyong-Su Park Bacterial vesicles have emerged as therapeutic drug candidates to treat a wide range of diseases, including cancer. However, critical concerns remain ...
Linking the gap from development to robust manufacturing
The complex journey of bringing a biologic to market – part 3 It is a critical shift for companies when transitioning from early development to clinical production, where you transfer ...
Viral vaccine manufacturing for clinical trials
Viral vaccines are entering a new era Vaccines have played a pivotal role in controlling infectious diseases for more than a century. Often regarded as one of the most impactful ...
Automation advances for cell harvesting in biomanufacturing
In a recent article in BioPharm International, NorthX Biologics’ Agnes Zimmer and Erica Johansson explore how new technologies are revolutionizing cell harvesting. They discuss the shift from traditional, labor-intensive methods ...
Bridging innovation and execution: The critical role of technology transfer
The complex journey of bringing a biologic to market – part 2 The journey from early development to commercial production in biologics is paved with complexity and few phases are ...
The importance of collaboration
The complex journey of bringing a biologic to market – part 1 Biologic drugs differ from traditional medicines as they are produced in living systems, making their development and manufacturing ...